SCHEMBL5895330

SCHEMBL5895330

O=C(O)C(=Cc1ccc(-c2ccccc2)o1)NC(=O)c1cccc(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 6/20 0.61
LMNA P02545 4/20 0.61
MAPT P10636 10/20 0.56
MITF O75030 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
HTT P42858 2/20 0.55
ALDH1A1 P00352 8/20 0.52
NPSR1 Q6W5P4 2/20 0.49
KDM4E B2RXH2 6/20 0.47
GAA P10253 5/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
HSP90AA1 P07900 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
POLB P06746 3/20 0.46
PKM P14618 2/20 0.46
RAD52 P43351 1/20 0.46
HPGD P15428 4/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5895324 1.00 MAPK1 (0.61) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895308 1.00 MAPK1 (0.61) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895090 0.93 MAPK1 (0.69) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895081 0.93 MAPK1 (0.69) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895072 0.93 MAPK1 (0.69) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895791 0.89 MAPT (0.67) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895812 0.89 MAPT (0.67) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895805 0.89 MAPT (0.67) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5895836 0.88 MAPT (0.56) MAPK1LMNAMAPTMITFSMN1; SMN2
SCHEMBL5896826 0.88 MAPT (0.56) MAPK1LMNAMAPTMITFSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI MAPK1 2559/4885LMNA 4047/4885MAPT 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.